Librela 3 years post launch; what do we know now?
15 Nov 2024
Platinum Suite - Level 3
Librela® was launched in 2021 and since then millions of dogs globally with osteoarthritis have benefited from this innovative monoclonal antibody therapy. This presentation will include safety and efficacy data from real world usage of Librela® and discuss how it is best used in practice to optimise outcomes for your osteoarthritic patients.
Learning Outcomes
• Gain insight into real world study data concerning usage, quality of life improvements and treatment compliance with Librela®
• Understand the pharmacovigilance process and SPC updates
• Understand the importance of the multimodal approach for patients with osteoarthritis
)
)
)
){kind=logo}
)
){kind=icon}
){kind=logo}
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}
)
)
){kind=logo}
)
)
)
){kind=logo}
)
)
){kind=logo}